MedTrace Logo

GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma

NCT05668884 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 93

Last updated 2026-01-14

No results posted yet for this study

Summary

In this phase 2 study, the investigators aim to evaluate the effects and safety of combined therapy using oxaliplatin and gemcitabine chemotherapy, Donafenib and Tislelizumab for patients with advanced biliary tract carcinoma.

Conditions

  • Biliary Tract Carcinoma

Interventions

COMBINATION_PRODUCT

Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab

Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab every 3 weeks

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Yiming Zhao, M.D. · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-18
Primary Completion
2026-12-31
Completion
2027-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05668884 on ClinicalTrials.gov